• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » InVivo adds patient to regenerative spinal scaffold trial

InVivo adds patient to regenerative spinal scaffold trial

January 19, 2017 By Sarah Faulkner

InVivo adds patient to regenerative spinal scaffold trialInVivo Therapeutics (NSDQ:NVIV) said today that it enrolled a new patient in the Inspire study of its neuro-spinal scaffold.

Principal investigator Dr. Travis Dumont performed the implantation earlier this week, 67 hours after the patient’s spinal cord injury happened.

“The implantation procedure of the neuro-spinal scaffold was successful, and the patient is doing well,” Dumont said in prepared remarks. “I look forward to following the patient’s progress going forward.”

“We are pleased at the rate of enrollment into Inspire over the past few months,” InVivo’s chairman & CEO Mark Perrin added. “We now have 11 patients enrolled and in follow up, and with a steady flow of new sites we expect enrollment to increase in the coming months.”

This week, the Cambridge, Mass.-based company also added another clinical site to its trial. The University of New Mexico Hospital marks the 30th clinical site participating in InVivo’s trial.

“I am pleased to be joining the Inspire study and look forward to the opportunity to safely investigate this innovative experimental therapy,” principal investigator Dr. Jeremy Lewis said in a statement.

“We welcome Dr. Lewis and the team at UNMH to the Inspire study,” Perrin said. “As the only Level I trauma center in the entire state of New Mexico, UNMH has a large catchment area that will be helpful for enrolling patients.”

Last week, the 1st U.S. Circuit Court of Appeals upheld the dismissal of a shareholder lawsuit against InVivo Therapeutics, saying that the plaintiff did not do enough to prove that the defendants committed securities fraud. The lead plaintiff, Edmond Ganem, accused InVivo and former CEO Frank Reynolds of inflating stock prices with false or misleading press releases regarding the company’s clinical trials.

The press releases in question date back to April and May 2013, when the company received approval from the FDA for its 1st clinical trial evaluating its biopolymer scaffold for spinal cord injury patients. Ganem alleged that statements in the press releases pertaining to the clinical trials projected timeline were false or misleading, and that InVivo left out details from the FDA’s approval letter such as the watchdog’s recommendation that the company modify its study design so it could serve as the basis for approval of a larger study.

After the 1st press release in April 2013 was published, InVivo’s stock price rose from $2.85 apiece to $3.19.

The appeals court ruled with the district court, concluding that the plaintiffs failed to prove that the omitted details delayed the timeline of the clinical trial.

At the beginning of this month, PixarBio (OTC:PXRB) and CEO Frank Reynolds today upped the ante in their pursuit of InVivo. Reynolds co-founded the regenerative medicine company and led it until his 2013 ouster.

PixarBio and Reynolds made their case for the merger by citing a -41.7% slide in the price of NVIV shares since January last year. The nearly 2,700-word press release detailed the merger, proposing a new entity called Reynolds Therapeutic Corp. The deal is expected to close during the 1st quarter, they said.

Filed Under: Clinical Trials, Implants, Spine, Surgical Tagged With: InVivo Therapeutics, PixarBio

More recent news

  • Alpheus Medical raises $52M for ultrasound-activated tumor therapy
  • Elucent Medical wins FDA breakthrough nod for in-body spatial intelligence system
  • EndoQuest Robotics completes first cases in pivotal surgical robot trial
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Intuitive Surgical is making a CEO change

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy